Pharmacopsychiatry 2012; 45(03): 100-107
DOI: 10.1055/s-0031-1291319
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

A Randomized, Waiting List-Controlled 12-Week Trial of Atomoxetine in Adults with ADHD

E. Sobanski
1   Central Institute of Mental Health Mannheim, Department of Psychiatry & Psychotherapy, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
D. Sabljic
1   Central Institute of Mental Health Mannheim, Department of Psychiatry & Psychotherapy, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
B. Alm
1   Central Institute of Mental Health Mannheim, Department of Psychiatry & Psychotherapy, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
C. Baehr
2   Ruprecht Karls University of Heidelberg , Department of Legal and Traffic Medicine , Heidelberg , Germany
,
R. W. Dittmann
3   Central Institute of Mental Health Mannheim, Eli Lilly Endowed Chair for Paediatric Psychopharmacology, Department of Child & Adolescent Psychiatry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
G. Skopp
2   Ruprecht Karls University of Heidelberg , Department of Legal and Traffic Medicine , Heidelberg , Germany
,
P. Strohbeck-Kuehner
2   Ruprecht Karls University of Heidelberg , Department of Legal and Traffic Medicine , Heidelberg , Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 09. Mai 2011
revised 16. September 2011

accepted 28. September 2011

Publikationsdatum:
15. Dezember 2011 (online)

Preview

Abstract

Background:

With the increasing recognition of adult attention-deficit/hyperactivity disorder (ADHD) there is an emerging need to investigate medication in this population.

Methods:

In this waiting list-controlled trial, 64 ADHD-patients (mean age 35.8±8.7 years) were randomly assigned to a daily dosage of up to 80 mg atomoxetine (Atx) or waiting list for 12-weeks. Primary outcome was the change of the observer-rated DSM-IV total ADHD score on the Conners’ Adult ADHD Rating Scales (CAARS-O:L DSM-IV total ADHD score) from baseline to endpoint. Other efficacy measures included self-rated CAARS-S:L DSM-IV total ADHD score, CAARS-O/S:L problems with self-concept and emotional lability score, Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation Score, and General Activities Score on the Quality of Life Enjoyment and Satisfaction Questionnaire. Efficacy measures were analysed in the per-protocol population.

Results:

Mean change in CAARS:O-L DSM-IV total ADHD score was  − 13.1±7.7 in the Atx vs.  − 0.4±4.8 in the control group (p<0.005). Treatment response (≥30% reduction) was 60.1% in the Atx vs. 0% in the waiting list group. The other efficacy measures also showed significant improvements. The overall incidence of adverse events (AEs) was 70.4% in the Atx group, the most frequent included fatigue, irritability, nausea and decreased appetite. In Atx-treated patients 18.5% discontinued early due to AEs.

Discussion:

Our results suggest that Atx is an effective treatment in adult ADHD. It reduces ADHD core and associated emotional symptoms and increases self-esteem and quality of life. AEs were consistent with those reported in other studies in adult ADHD.